BACKGROUND: Risk factors for the development of therapy-related leukemia (TRL), an often lethal late complication of cytotoxic therapy, remain poorly understood and may differ for survivors of different malignancies. Survivors of breast cancer (BC) now account for the majority of TRL cases, making the study of TRL risk factors in this population a priority. METHODS: Subjects with TRL after cytotoxic therapy for a primary BC were identified from the TRL registry at The University of Chicago. Those with an available germline DNA sample were screened with a comprehensive gene panel covering known inherited BC susceptibility genes. Clinical and TRL characteristics of all subjects and those with identified germline mutations were described. RESULTS: Nineteen of 88 survivors of BC with TRL (22%) had an additional primary cancer and 40 of the 70 survivors with an available family history (57%) had a close relative with breast, ovarian, or pancreatic cancer. Of the 47 subjects with available DNA, 10 (21%) were found to carry a deleterious inherited mutation in BRCA1 (3 subjects; 6%), BRCA2 (2 subjects; 4%), TP53 (tumor protein p53) (3 subjects; 6%), CHEK2 (checkpoint kinase 2) (1 subject; 2%), and PALB2 (partner and localizer of BRCA2) (1 subject; 2%). CONCLUSIONS: Survivors of BC with TRL have personal and family histories suggestive of inherited cancer susceptibility and frequently carry germline mutations in BC susceptibility genes. The data from the current study support the role of these genes in TRL risk and suggest that long-term follow-up studies of women with germline mutations who are treated for BC and functional studies of the effects of heterozygous mutations in these genes on bone marrow function after cytotoxic exposures are warranted. Cancer 2016;122:304-311.
BACKGROUND: Risk factors for the development of therapy-related leukemia (TRL), an often lethal late complication of cytotoxic therapy, remain poorly understood and may differ for survivors of different malignancies. Survivors of breast cancer (BC) now account for the majority of TRL cases, making the study of TRL risk factors in this population a priority. METHODS: Subjects with TRL after cytotoxic therapy for a primary BC were identified from the TRL registry at The University of Chicago. Those with an available germline DNA sample were screened with a comprehensive gene panel covering known inherited BC susceptibility genes. Clinical and TRL characteristics of all subjects and those with identified germline mutations were described. RESULTS: Nineteen of 88 survivors of BC with TRL (22%) had an additional primary cancer and 40 of the 70 survivors with an available family history (57%) had a close relative with breast, ovarian, or pancreatic cancer. Of the 47 subjects with available DNA, 10 (21%) were found to carry a deleterious inherited mutation in BRCA1 (3 subjects; 6%), BRCA2 (2 subjects; 4%), TP53 (tumor protein p53) (3 subjects; 6%), CHEK2 (checkpoint kinase 2) (1 subject; 2%), and PALB2 (partner and localizer of BRCA2) (1 subject; 2%). CONCLUSIONS: Survivors of BC with TRL have personal and family histories suggestive of inherited cancer susceptibility and frequently carry germline mutations in BC susceptibility genes. The data from the current study support the role of these genes in TRL risk and suggest that long-term follow-up studies of women with germline mutations who are treated for BC and functional studies of the effects of heterozygous mutations in these genes on bone marrow function after cytotoxic exposures are warranted. Cancer 2016;122:304-311.
Authors: Sonali M Smith; Michelle M Le Beau; Dezheng Huo; Theodore Karrison; Ronald M Sobecks; John Anastasi; James W Vardiman; Janet D Rowley; Richard A Larson Journal: Blood Date: 2003-03-06 Impact factor: 22.113
Authors: Lindsay M Morton; Graça M Dores; Margaret A Tucker; Clara J Kim; Kenan Onel; Ethel S Gilbert; Joseph F Fraumeni; Rochelle E Curtis Journal: Blood Date: 2013-02-14 Impact factor: 22.113
Authors: Tom Walsh; Ming K Lee; Silvia Casadei; Anne M Thornton; Sunday M Stray; Christopher Pennil; Alex S Nord; Jessica B Mandell; Elizabeth M Swisher; Mary-Claire King Journal: Proc Natl Acad Sci U S A Date: 2010-06-28 Impact factor: 11.205
Authors: Antonio C Wolff; Amanda L Blackford; Kala Visvanathan; Hope S Rugo; Beverly Moy; Lori J Goldstein; Keith Stockerl-Goldstein; Leigh Neumayer; Terry S Langbaum; Richard L Theriault; Melissa E Hughes; Jane C Weeks; Judith E Karp Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine Journal: N Engl J Med Date: 2012-03-14 Impact factor: 91.245
Authors: Eduard Schulz; Angelika Valentin; Peter Ulz; Christine Beham-Schmid; Karin Lind; Verena Rupp; Herwig Lackner; Albert Wölfler; Armin Zebisch; Werner Olipitz; Jochen Geigl; Andrea Berghold; Michael R Speicher; Heinz Sill Journal: J Med Genet Date: 2012-05-31 Impact factor: 6.318
Authors: Alan H Shih; Stephen S Chung; Emily K Dolezal; Su-Jiang Zhang; Omar I Abdel-Wahab; Christopher Y Park; Stephen D Nimer; Ross L Levine; Virginia M Klimek Journal: Haematologica Date: 2013-01-24 Impact factor: 9.941
Authors: Colin C Pritchard; Stephen J Salipante; Karen Koehler; Christina Smith; Sheena Scroggins; Brent Wood; David Wu; Ming K Lee; Suzanne Dintzis; Andrew Adey; Yajuan Liu; Keith D Eaton; Renato Martins; Kari Stricker; Kim A Margolin; Noah Hoffman; Jane E Churpek; Jonathan F Tait; Mary-Claire King; Tom Walsh Journal: J Mol Diagn Date: 2013-11-02 Impact factor: 5.568
Authors: Mohammad Faizan Zahid; Aric Parnes; Bipin N Savani; Mark R Litzow; Shahrukh K Hashmi Journal: World J Stem Cells Date: 2016-08-26 Impact factor: 5.326
Authors: Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2016-11-28 Impact factor: 22.113
Authors: David Ullman; Erin Baumgartner; Nicholas Wnukowski; Gabe Koenig; Fady M Mikhail; Peter Pavlidakey; Deniz Peker Journal: Mol Clin Oncol Date: 2017-12-08
Authors: Michele Carbone; Ivano Amelio; El Bachir Affar; James Brugarolas; Lisa A Cannon-Albright; Lewis C Cantley; Webster K Cavenee; Zhijian Chen; Carlo M Croce; Alan D' Andrea; David Gandara; Carlotta Giorgi; Wei Jia; Qing Lan; Tak Wah Mak; James L Manley; Katsuhiko Mikoshiba; Jose N Onuchic; Harvey I Pass; Paolo Pinton; Carol Prives; Nathaniel Rothman; Said M Sebti; James Turkson; Xifeng Wu; Haining Yang; Herbert Yu; Gerry Melino Journal: Cell Death Differ Date: 2018-10-15 Impact factor: 15.828